very, development and commercialization of drugs and delivery technologies for the treatment of diseases affecting the ear including hearing loss. Audion, which was founded by Albert Edge, Helmuth van Es and Rolf Jan Rutten, has technologies and molecules that originated from Albert Edge's research at the Mass Eye and Ear and then were exclusively licensed to Audion. For more information please visit www.audiontherapeutics.com
About Mass Eye and Ear The Mass Eye and Ear is a specialty hospital providing outstanding patient care for disorders of the eye, ear, nose, throat, head and neck. Mass Eye and Ear is an international leader in hearing loss research and a teaching partner of Harvard Medical School. For more information please visit www.MassEyeAndEar.org.
About Sanofi Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "Page: 1 2 3 4 5 Related medicine technology :1
. Sanofi Pasteur Donates Tdap Vaccine to Aid Storm Victims2
. sanofi-aventis: Strong Performance of Growth Platforms in Q1 20113
. Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants4
. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research5
. Sanofi-Aventis Completes Acquisition of Genzyme Corporation6
. Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation7
. Navinta LLC is Pleased to Announce US FDA Approval of Sodium Ferric Gluconate Injection in Sucrose [a generic equivalent of Ferrlecit® Injection by Sanofi Aventis] Based on Its Proprietary Technology8
. Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective9
. Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments10
. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer11
. Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China